Anämie bei chronisch entzündlichen Darmerkrankungen: Ein oft unterschätztes Problem

Literatur

• 1 Black A J, McLeod H L, Capell H A. et al . Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine.  Ann Intern Med. 1998;  129 716-718
• 2 Cleeland C S, Demetri G D, Glaspy J. et al . Identifying hemoglobin level for optimal quality of life: results of an incremental analysis.  Proc Am Soc Clin Oncol. 1999;  18 A2215
• 3 Colombel J F, Ferrari N, Debuysere H. et al . Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy.  Gastroenterology. 2000;  118 1025-1030
• 4 Demetri G D, Kris M, Wade J. et al. Procrit Study Group . Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study.  J Clin Oncol. 1998;  16 3412-3425
• 5 Dohil R, Hassall E, Wadsworth L D. et al . Recombinant human erythropoietin for treatment of anemia of chronic disease in children with Crohn’s disease.  J Pediatr. 1998;  132 155-159
• 6 Gasche C, Dejaco C, Waldhoer T. et al . Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial.  Ann Intern Med. 1997;  126 782-787
• 7 Gasche C, Dejaco C, Reinisch W. et al . Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin.  Digestion. 1999;  60 262-267
• 8 Gasche C, Waldhoer T, Feichtenschlager T. et al . Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia.  Am J Gastroenterol. 2001;  96 2382-2387
• 9 Horina J H, Petritsch W, Schmid C R. et al . Treatment of anemia in inflammatory bowel disease with recombinant human erythropoietin: results in three patients.  Gastroenterology. 1993;  104 1828-1831
• 10 Leitgeb C, Pecherstorfer M, Fritz E. et al . Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin.  Cancer. 1994;  73 2535-2542
• 11 Ludwig H, Strasser K. Symptomatology of anemia.  Semin Oncol. 2001;  28 7-14
• 12 Macdougall I C. Quality of life and anemia: the nephrology experience.  Semin Oncol. 1998;  25 39-42
• 13 Macdougall I C. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP).  Nephrol Dial Transplant. 2001;  16 14-21 (Suppl 3)
• 14 Oldenburg B, Koningsberger J C, Van Berge Henegouwen G P. et al . Iron and inflammatory bowel disease.  Aliment Pharmacol Ther. 2000;  15 429-438
• 15 Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency.  Blood. 1997;  89 1052-1057
• 16 Schreiber S, Howaldt S, Schnoor M. et al . Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease.  N Engl J Med. 1996;  334 619-623
• 17 Thomson A B, Brust R, Ali M A. et al . Iron deficiency in inflammatory bowel disease. Diagnostic efficacy of serum ferritin.  Am J Dig Dis. 1978;  23 705-709
• 18 Zanen A L, Adriaansen H J, van Bommel E F. et al . »Oversaturation« of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients.  Nephrol Dial Transplant. 1996;  11 820-824

Korrespondenz